Packer M, Medina N, Yushak M, Lee W H
Br Heart J. 1985 Sep;54(3):298-304. doi: 10.1136/hrt.54.3.298.
The relation between plasma renin activity before treatment and the haemodynamic and clinical responses to converting enzyme inhibition was determined in 100 consecutive patients with severe chronic heart failure who were treated with captopril or enalapril. Initial doses of captopril produced significant increases in cardiac index and decreases in left ventricular filling pressure, mean arterial pressure, mean right atrial pressure, heart rate, and systemic vascular resistance that varied linearly with the pretreatment value for plasma renin activity. In contrast, there was no relation between the pretreatment activity and the magnitude of haemodynamic improvement after 1-3 months of treatment with the converting enzyme inhibitors, and, consequently, a similar proportion of patients with a high (greater than 6 ng/ml/h; greater than 4.62 mmol/l/h), intermediate (2-6 ng/ml/h; 1.54-4.62 mmol/l/h), and low (less than 2 ng/ml/h; less than 1.54 mmol/l/h) pretreatment value improved clinically during long term treatment (64%, 60%, and 64% respectively). Long term survival after one, two, and three years was similar in the three groups. Estimating the degree of activation of the renin-angiotensin system by measuring pretreatment plasma renin activity fails to predict the long term haemodynamic or clinical responses to converting enzyme inhibitors in patients with severe chronic heart failure, and thus appears to be of limited value in selecting those patients likely to benefit from treatment with these drugs.
在100例连续的重度慢性心力衰竭患者中,测定了治疗前血浆肾素活性与对转换酶抑制的血流动力学及临床反应之间的关系,这些患者接受了卡托普利或依那普利治疗。卡托普利的初始剂量使心脏指数显著增加,左心室充盈压、平均动脉压、平均右心房压、心率和全身血管阻力降低,且这些变化与血浆肾素活性的治疗前值呈线性相关。相比之下,治疗前活性与转换酶抑制剂治疗1 - 3个月后的血流动力学改善程度之间没有关系,因此,治疗前值高(大于6 ng/ml/h;大于4.62 mmol/l/h)、中(2 - 6 ng/ml/h;1.54 - 4.62 mmol/l/h)、低(小于2 ng/ml/h;小于1.54 mmol/l/h)的患者在长期治疗期间临床改善的比例相似(分别为64%、60%和64%)。三组患者1年、2年和3年后的长期生存率相似。通过测量治疗前血浆肾素活性来估计肾素 - 血管紧张素系统的激活程度,无法预测重度慢性心力衰竭患者对转换酶抑制剂的长期血流动力学或临床反应,因此在选择可能从这些药物治疗中获益的患者方面似乎价值有限。